CRISPR Therapeutics (NASDAQ:CRSP) is one of the best emerging technology stocks to invest in. On December 22, CRISPR Therapeutics released a comprehensive clinical update on zugocaptagene geleucel ...
Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) stock declines while market improves: Some information for investors
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $54.21, marking a -4.71% move from the previous day. The stock's performance was behind the S&P 500's daily gain of 0.26%. At the ...
Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made just one trade on Friday, December 26, according to its daily fund disclosures. The firm added to its position in gene-editing company CRISPR ...
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its ...
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic priorities and anticipated ...
On December 24, Kevin Simpson of Capital Wealth Planning joined ‘Closing Bell’ on CNBC to talk about AI tailwinds and the diverging tech picture. Given the current market dynamics, Simpson confirmed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results